A number of other analysts have also recently commented on SRNE. HC Wainwright set a $40.00 price target on Sorrento Therapeutics and gave the company a buy rating in a research note on Friday, March 22nd. B. Riley raised their price target on shares of Sorrento Therapeutics from $10.50 to $12.00 and gave the stock a buy rating in a research note on Wednesday, March 20th. Finally, Zacks Investment Research cut shares of Sorrento Therapeutics from a hold rating to a sell rating in a research note on Saturday, February 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $20.67.
Shares of Sorrento Therapeutics stock opened at $3.64 on Wednesday. The company has a current ratio of 1.60, a quick ratio of 2.91 and a debt-to-equity ratio of 2.35. Sorrento Therapeutics has a 52-week low of $1.80 and a 52-week high of $8.25.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc, a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.